Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9200
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheng, Chao-Neng | - |
dc.contributor.author | Li, Sin-Syue | - |
dc.contributor.author | Yeh, Yun-Hsuan | - |
dc.contributor.author | Shen, Ching-Fen | - |
dc.contributor.author | -Shiuh Chen, Jiann | - |
dc.date.accessioned | 2024-12-18T02:36:45Z | - |
dc.date.available | 2024-12-18T02:36:45Z | - |
dc.date.issued | 2022-04-01 | - |
dc.identifier.issn | 1684-1182 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/9200 | - |
dc.description.abstract | Abstract From January 2019 to May 2021, 11 children underwent allogeneic stem cell transplantation at our institute. Four of them received letermovir for cytomegalovirus prophylaxis. Three children, none of whom received prophylaxis, experienced cytomegalovirus reactivation. Letermovir is a promising medication for use in cytomegalovirus prophylaxis in children. Further studies are warranted. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Taiwan LLC | en_US |
dc.subject | Children; | en_US |
dc.subject | Cytomegalovirus; | en_US |
dc.subject | Hematopoietic stem cell transplantation; | en_US |
dc.subject | Letermovir; | en_US |
dc.subject | Prophylaxis | en_US |
dc.title | Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 55 NO 2 2022 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
323-327.pdf | 668.2 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.